Enteritis - 30 Studies Found
Terminated |
: Campylobacter Enteritis and PI-BD: Dietary Reduction in Carbohydrates :
: 2014-09-02 :
|
Completed |
: Plasma Citrulline Concentration in Tropical Enteropathy :
|
Completed |
: Efficacy of Metronidazole Versus Metronidazole and Rifampin in CDAD Treatment :
|
ACTIVE_NOT_RECRUITING |
: Serologic Assay Validation and Proficiency Testing of HIL-214 in Adults : Gastroenteritis : 2024-11-23 : HIL-214 |
ACTIVE_NOT_RECRUITING |
: Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age. : Norovirus Acute Gastroenteritis : 2024-11-23 : Sterile liquid for injection |
ACTIVE_NOT_RECRUITING |
: Safety and Immunogenicity of HIL-214 With Routine Pediatric Vaccines : Gastroenteritis : 2024-11-23 : 2 injections - given at 4 months and the second at 6 months of age. |
COMPLETED |
: Admission Pattern Among Children With Gastro-intestinal Infections Before and During the Covid-19 Pandemic : Gastroenteritis : 2024-11-23 |
COMPLETED |
: Phase I Norovirus Challenge Model : Gastroenteritis Norovirus : 2024-11-23 : Subjects will be NPO (nothing by mouth) for at least 90 minutes followed by ingestion of 60 mL of a 2% sodium bicarbonate solution by mouth. 2 minutes |
RECRUITING |
: Associations of Fecal Bile Acid Profile and Intestinal Flora With Chronic Radiation Enteritis : Radiation Enteritis : 2024-11-23 |
COMPLETED |
: Clinical Trial of Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris) : Acute Gastroenteritis : 2024-11-23 : Active ingredients: recombinant ReNoV GI.1-VP1 protein, recombinant ReNoV GII.3-VP1 protein, recombinant ReNoV GII.4-VP1 protein and recombinant Re |